PDS Biotechnology Corporation (FRA:EU6)

Market Cap	10.72M -79.3%
Revenue (ttm)	n/a
Net Income	-29.47M
EPS	-0.56
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1900
Previous Close	0.1890
Day's Range	0.1900 - 0.1900
52-Week Range	0.1710 - 1.2150
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EU6

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error